Evidence map›Paper›PMID 26694080›Full record

ReviewAlimentary pharmacology & therapeutics2016

Review article: the global emergence of Helicobacter pylori antibiotic resistance.

I Thung, H Aramin, V Vavinskaya, S Gupta, J Y Park, S E Crowe, M A Valasek

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alimentary pharmacology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06687499 (The Study of Adding Bismuth on Susceptibility-based Regimen Strategy to Enhance the Eradication Rate for Multi-resistant H. Pylori Infection), which is not on this map. Cited by 361 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
361citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06687499 phase4completednot on this mapstarted 2022, after this paper: background citation

The Study of Adding Bismuth on Susceptibility-based Regimen Strategy to Enhance the Eradication Rate for Multi-resistant H. Pylori Infection

TypeinterventionalSponsorNational Cheng-Kung University HospitalRan2022 to 2024Enrolled46ConditionsHelicobacter Pylori, Drug Resistance, MultipleArmsBismuth-based susceptibility-guided treatment
3 · Its place in the literature

Who cites it

361 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. First regional consensus on the management ofWorld journal of gastroenterology · 2025
    Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Vonoprazan-amoxicillin dual therapy forWorld journal of gastroenterology · 2024
    Trial
  15. Trial
  16. Study of the effect of LactobacillusFrontiers in immunology · 2023
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Frontiers in cellular and infection microbiology · 2022
    Trial

301 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

I ThungDivision of Anatomic Pathology, Department of Pathology, University of California San Diego Medical Center, San Diego, CA, USA.
H AraminDivision of Anatomic Pathology, Department of Pathology, University of California San Diego Medical Center, San Diego, CA, USA.
V VavinskayaDivision of Anatomic Pathology, Department of Pathology, University of California San Diego Medical Center, San Diego, CA, USA.
S GuptaDivision of Gastroenterology, Department of Medicine, University of California San Diego Medical Center, La Jolla, CA, USA.
J Y ParkDepartment of Pathology and the Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX, USA.
S E CroweDivision of Gastroenterology, Department of Medicine, University of California San Diego Medical Center, La Jolla, CA, USA.
M A ValasekDivision of Anatomic Pathology, Department of Pathology, University of California San Diego Medical Center, San Diego, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma.

aimTo review recent trends in H. pylori antibiotic resistance rates, and to discuss diagnostics and treatment paradigms.

methodsA PubMed literature search using the following keywords: Helicobacter pylori, antibiotic resistance, clarithromycin, levofloxacin, metronidazole, prevalence, susceptibility testing.

resultsThe prevalence of bacterial antibiotic resistance is regionally variable and appears to be markedly increasing with time in many countries. Concordantly, the antimicrobial eradication rate of H. pylori has been declining globally. In particular, clarithromycin resistance has been rapidly increasing in many countries over the past decade, with rates as high as approximately 30% in Japan and Italy, 50% in China and 40% in Turkey; whereas resistance rates are much lower in Sweden and Taiwan, at approximately 15%; there are limited data in the USA. Other antibiotics show similar trends, although less pronounced.

conclusionsSince the choice of empiric therapies should be predicated on accurate information regarding antibiotic resistance rates, there is a critical need for determination of current rates at a local scale, and perhaps in individual patients. Such information would not only guide selection of appropriate empiric antibiotic therapy but also inform the development of better methods to identify H. pylori antibiotic resistance at diagnosis. Patient-specific tailoring of effective antibiotic treatment strategies may lead to reduced treatment failures and less antibiotic resistance.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsChinaClarithromycinDrug Resistance, MicrobialFemaleGlobal HealthHelicobacter InfectionsHelicobacter pyloriHumansLevofloxacinMetronidazoleMicrobial Sensitivity TestsPrevalenceTreatment FailureTreatment OutcomeAnti-Bacterial AgentsAnti-Infective AgentsClarithromycinLevofloxacinMetronidazole

Identifiers

PMID26694080
PMCPMC5064663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.